IFNGR1 and melanoma: This was further confirmed in preclinical experiments using a B16 melanoma model with IFNGR1 knock-down (IFNGR1KD) that showed impaired IFN-γ signaling and reduced sensitivity to anti-CTLA-4 therapy [93].